No connection

Search Results

MTD

NEUTRAL
$1240.15 Live
Mettler-Toledo International Inc. · NYSE
Target $1488.31 (+20.0%)
$1029.23 52W Range $1525.17
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 30, 2026
Market cap
$25.11B
P/E
29.5
ROE
N/A
Profit margin
21.6%
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
MTD exhibits exceptional operational health with a Piotroski F-Score of 8/9 and a strong ROA of 20.35%, indicating a highly efficient business model. The stock is currently trading almost exactly at its growth-based intrinsic value of $1240.18, suggesting it is fairly valued. However, the outlook is tempered by a bearish technical trend and significant insider selling by the CEO and CFO. While analyst consensus remains a 'buy' with a target of $1488.31, the high PEG ratio of 2.68 suggests that current growth may not fully justify a significant premium over the current price.

Key Strengths

Strong deterministic health (Piotroski F-Score 8/9)
Excellent profitability margins (Gross 59.37%, Operating 30.71%)
Consistent earnings track record with 3/4 recent beats and long-term stability
High Return on Assets (ROA) of 20.35%
Strong analyst support with a mean target price of $1488.31

Key Risks

Bearish insider sentiment with selling from CEO and CFO
High PEG ratio (2.68) indicating potential overvaluation relative to growth
Bearish technical trend (0/100 score)
Low quick ratio (0.70) suggesting tight short-term liquidity
Negative Price/Book ratio indicating potential equity depletion via buybacks
AI Fair Value Estimate
Based on comprehensive analysis
$1240.18
0.0% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
61
Strong
Value
50
Future
70
Past
90
Health
95
Dividend
0
AI Verdict
Fundamentally strong but momentum-challenged
Key drivers: Piotroski F-Score, Intrinsic Value alignment, Insider selling, Earnings consistency
Confidence
90%
Value
50/100

P/E of 29.50 is reasonable, but PEG of 2.68 suggests growth is expensive.

Positives
  • Trading at intrinsic value
Watchpoints
  • High PEG ratio
  • Negative P/B ratio
Future
70/100

Growth is steady but not explosive.

Positives
  • 17% YoY earnings growth
  • Consistent earnings beats
Watchpoints
  • Moderate revenue growth (8.1%)
Past
90/100

Operational excellence is decoupled from long-term stock price appreciation.

Positives
  • 25 quarters of reliable earnings performance
  • Strong historical margin maintenance
Watchpoints
  • Negative 3Y and 5Y price change
Health
95/100

Extremely strong financial health based on deterministic scoring.

Positives
  • Piotroski F-Score 8/9
  • High ROA
Watchpoints
  • Quick ratio below 1.0
Dividend
0/100

Company does not return value via dividends.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0% payout ratio

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$1240.15
Analyst Target
$1488.31
Upside/Downside
+20.0%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for MTD and closest competitors.

Updated 2026-04-29
MTD
Mettler-Toledo International Inc.
Primary
5Y
-5.6%
3Y
-18.4%
1Y
+16.4%
6M
-11.1%
1M
-0.6%
1W
-5.3%
IQV
IQVIA Holdings Inc.
Peer
5Y
-32.5%
3Y
-15.5%
1Y
+5.9%
6M
-27.1%
1M
-4.3%
1W
-9.5%
DXC
DexCom, Inc.
Peer
5Y
-31.7%
3Y
-50.1%
1Y
-22.2%
6M
-32.1%
1M
-11.2%
1W
+5.6%
HUM
Humana Inc.
Peer
5Y
-46.1%
3Y
-55.1%
1Y
-11.3%
6M
-21.4%
1M
+38.4%
1W
+5.7%
BNT
BioNTech SE
Peer
5Y
-20.9%
3Y
-28.6%
1Y
-2.4%
6M
-9.9%
1M
-17.3%
1W
+2.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
29.5
Forward P/E
24.22
PEG Ratio
2.68
P/B Ratio
-1068.17
P/S Ratio
6.24
EV/Revenue
6.81
EV/EBITDA
22.61
Market Cap
$25.11B

Profitability

Profit margins and return metrics

Profit Margin 21.59%
Operating Margin 30.71%
Gross Margin 59.37%
ROE N/A
ROA 20.35%

Growth

Revenue and earnings growth rates

Revenue Growth +8.1%
Earnings Growth +17.0%
Q/Q Revenue Growth +8.1%
Q/Q Earnings Growth +13.3%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
1.14
Good
Quick Ratio
0.7
Poor
Cash/Share
$3.29

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$1.1B
Gross Margin
59.8%
Op. Margin
30.4%
Net Margin
25.3%
Total Assets
$3.7B
Liabilities
$3.7B
Equity
$-0.0B
Debt/Equity
-158.08x
Operating CF
$0.2B
CapEx
$-0.0B
Free Cash Flow
$0.2B
FCF Yield
82%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-02-05
$13.36
+4.3% surprise
2025-11-06
$11.15
+4.6% surprise
2025-07-31
$10.09
+5.1% surprise

Healthcare Sector Comparison

Comparing MTD against 571 companies in the Healthcare sector (37 bullish, 174 neutral, 360 bearish)
P/E Ratio
29.5
This Stock
vs
73.1
Sector Avg
-59.6% (Discount)
Profit Margin
21.59%
This Stock
vs
-16.0%
Sector Avg
-234.9% (Weaker)
Revenue Growth
8.1%
This Stock
vs
121.82%
Sector Avg
-93.4% (Slower)
Current Ratio
1.14
This Stock
vs
4.44
Sector Avg
-74.4% (Weaker)

Similar Companies

Peer comparison within the same industry

MTD Mettler-Toledo...
NEUTRAL
Mkt Cap
$25.1B
P/E
29.5
ROE
-%
Price
$1240.15
IQV IQVIA Holdings Inc.
BULLISH
Mkt Cap
$26.7B
P/E
20.3
ROE
21.4%
Price
$158.98
 Compare with MTD
DXCM DexCom, Inc.
BULLISH
Mkt Cap
$23.3B
P/E
32.3
ROE
30.6%
Price
$58.06
 Compare with MTD
HUM Humana Inc.
BEARISH
Mkt Cap
$27.6B
P/E
23.4
ROE
7.0%
Price
$229.72
 Compare with MTD
BNTX BioNTech SE
BEARISH
Mkt Cap
$22.3B
P/E
-
ROE
-5.9%
Price
$88.88
 Compare with MTD

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

TOKICH MICHAEL JOSEPH
Director
Stock Award
2026-02-17
50 shares
VADALA SHAWN P.
Chief Financial Officer
Sell
2026-02-10
800 shares · $1,128,096
VADALA SHAWN P.
Chief Financial Officer
Option Exercise
2026-02-10
800 shares · $476,248
GUERONNIERE MARC DE LA
Officer
Sell
2025-11-25
6,055 shares · $9,010,900
GUERONNIERE MARC DE LA
Officer
Option Exercise
2025-11-25
6,055 shares · $5,312,256
VADALA SHAWN P.
Chief Financial Officer
Sell
2025-11-25
2,025 shares · $2,999,300
VADALA SHAWN P.
Chief Financial Officer
Option Exercise
2025-11-25
2,025 shares · $1,283,700
KELLER GERRY
Officer
Sell
2025-11-21
236 shares · $334,785
KELLER GERRY
Officer
Option Exercise
2025-11-21
236 shares · $169,358
KALTENBACH PATRICK
Chief Executive Officer
Sell
2025-11-12
2,000 shares · $2,924,998
KALTENBACH PATRICK
Chief Executive Officer
Option Exercise
2025-11-12
2,000 shares · $2,049,100
KELLER GERRY
Officer
Stock Award
2025-11-11
65 shares
DIGGELMANN ROLAND D
Director
Stock Award
2025-11-11
157 shares
DOAT-LE BIGOT DOMITILLE
Director
Stock Award
2025-11-11
63 shares
WONG ANN PING RICHARD
Officer
Stock Award
2025-11-11
67 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A
DEF 14A
2026-03-18

MTD filed a definitive proxy statement on March 18, 2026, providing shareholders with necessary information to vote at the company's annual meeting.

10-K
10-K
2026-02-06

MTD filed its annual 10-K report on February 6, 2026. The provided excerpts do not contain specific financial data or detailed risk factors, limiting the analysis to the confirmation of the filing's submission.

8-K
8-K
2026-02-05

MTD filed an 8-K on February 5, 2026, likely to announce its financial results for the fourth quarter and full year ended December 31, 2025.

8-K
8-K
2026-01-20

MTD filed an 8-K on January 20, 2026, likely to announce its financial results for the preceding fiscal period.

10-Q
10-Q
2025-11-07

MTD filed its 10-Q on November 7, 2025, though the provided excerpt contains no specific financial highlights. The filing includes a section on Risk Factors under Item 1A, but detailed risk descriptions were not included in the available text.

8-K
8-K
2025-11-06

MTD likely filed this 8-K to report its third-quarter financial results.

8-K
8-K
2025-10-23

MTD filed an 8-K on October 23, 2025, likely to announce its third-quarter financial results.

8-K
8-K
2025-08-04

MTD filed an 8-K on August 4, 2025, likely to announce its second-quarter financial results.

10-Q
10-Q
2025-08-01

MTD filed its 10-Q on August 1, 2025, though the provided excerpt contains no specific financial performance data. The filing includes a section on Risk Factors under Item 1A, but detailed risk descriptions were not included in the available text.

8-K
8-K
2025-08-01

MTD filed an 8-K on August 1, 2025, likely to announce its second-quarter financial results.

8-K
8-K
2025-05-12
8-K
8-K
2025-05-06
10-Q
10-Q
2025-05-02
8-K
8-K
2025-05-01
DEF 14A
DEFINITIVE PROXY STATEMENT
2025-03-17
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
13 analysts
Barclays
2026-04-14
Maintains
Overweight Overweight
Evercore ISI Group
2026-04-06
Maintains
Outperform Outperform
Jefferies
2026-03-20
up
Hold Buy
Morgan Stanley
2026-02-10
Maintains
Equal-Weight Equal-Weight
Barclays
2025-12-15
Maintains
Overweight Overweight
Wells Fargo
2025-12-15
Maintains
Equal-Weight Equal-Weight
Goldman Sachs
2025-12-09
init
Neutral
Morgan Stanley
2025-12-02
init
Equal-Weight
Citigroup
2025-11-10
Maintains
Buy Buy
Barclays
2025-11-10
Maintains
Overweight Overweight

Past News Coverage

Recent headlines mentioning MTD from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile